Capecitabine Teva

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
01-02-2024
Produktens egenskaper Produktens egenskaper (SPC)
01-02-2024

Aktiva substanser:

capecitabine

Tillgänglig från:

Teva Pharma B.V.

ATC-kod:

L01BC06

INN (International namn):

capecitabine

Terapeutisk grupp:

Antineoplastic agents

Terapiområde:

Colonic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Stomach Neoplasms

Terapeutiska indikationer:

Capecitabine Teva is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer.Capecitabine Teva is indicated for the treatment of metastatic colorectal cancer.Capecitabine Teva is indicated for first‑line treatment of advanced gastric cancer in combination with a platinum‑based regimen.Capecitabine Teva in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine Teva is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

Produktsammanfattning:

Revision: 15

Bemyndigande status:

Authorised

Tillstånd datum:

2012-04-20

Bipacksedel

                                40
B. PACKAGE LEAFLET
41
PACKAGE LEAFLET: INFORMATION FOR THE USER
_ _
CAPECITABINE TEVA 150 MG FILM-COATED TABLETS
CAPECITABINE TEVA 500 MG FILM-COATED TABLETS
capecitabine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Capecitabine Teva is and what it is used for
2.
What you need to know before you take Capecitabine Teva
3.
How to take Capecitabine Teva
4.
Possible side effects
5.
How to store Capecitabine Teva
6.
Contents of the pack and other information
1.
WHAT CAPECITABINE TEVA IS AND WHAT IT IS USED FOR
Capecitabine Teva belongs to the group of medicines called "cytostatic
medicines", which stop the
growth of cancer cells. Capecitabine Teva contains capecitabine, which
itself is not a cytostatic
medicine. Only after being absorbed by the body is it changed into an
active anti-cancer medicine
(more in tumour tissue than in normal tissue).
Capecitabine Teva is used in the treatment of colon, rectal, gastric,
or breast cancers. Furthermore,
Capecitabine Teva is used to prevent new occurrence of colon cancer
after complete removal of the
tumour by surgery.
Capecitabine Teva may be used either alone or in combination with
other medicines.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE CAPECITABINE TEVA
_ _
DO NOT TAKE CAPECITABINE TEVA_ _
-
if you are allergic to capecitabine or any of the other ingredients of
this medicine (listed in
section 6). You must inform your doctor if you know that you have an
allergy or over-reaction
to this medicine,
-
if you previously have had severe reactions to fluor
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1. NAME OF THE MEDICINAL PRODUCT
Capecitabine Teva 150 mg film-coated tablets
Capecitabine Teva 500 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Capecitabine Teva 150 mg film-coated tablets
Each film-coated tablet contains 150 mg capecitabine.
Capecitabine Teva 500 mg film-coated tablets
Each film-coated tablet contains 500 mg capecitabine.
Excipient with known effect
_Capecitabine Teva 150 mg film-coated tablets _
Each film-coated tablet contains 15.6 mg lactose.
_Capecitabine Teva 500 mg film-coated tablets _
Each film-coated tablet contains 52.0 mg lactose.
For the full list of excipients, see section 6.1.
_ _
3.
PHARMACEUTICAL FORM
Film-coated tablet
Capecitabine Teva 150 mg film-coated tablets
The film-coated tablets are oval biconvex light peach, 11.5 mm x 5.4
mm with inscription “C” on one
side and “150”on the other side.
Capecitabine Teva 500 mg film-coated tablets
The film-coated tablets are oval biconvex light peach, 16.0 mm x 8.5
mm with inscription “C” on one
side and “500”on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Capecitabine Teva is indicated for the treatment of:
-
for the adjuvant treatment of patients following surgery of stage III
(Dukes’ stage C) colon cancer
(see section 5.1).
-
metastatic colorectal cancer (see section 5.1).
-
first-line treatment of advanced gastric cancer in combination with a
platinum-based regimen (see
section 5.1).
-
in combination with docetaxel (see section 5.1) for the treatment of
patients with locally advanced
or metastatic breast cancer after failure of cytotoxic chemotherapy.
Previous therapy should have
included an anthracycline.
-
as monotherapy for the treatment of patients with locally advanced or
metastatic breast cancer after
failure of taxanes and an anthracycline containing chemotherapy
regimen or for whom further
anthracycline therapy is not indicated.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Capecitabine Teva should only be prescribed by
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 01-02-2024
Produktens egenskaper Produktens egenskaper bulgariska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 29-07-2020
Bipacksedel Bipacksedel spanska 01-02-2024
Produktens egenskaper Produktens egenskaper spanska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 29-07-2020
Bipacksedel Bipacksedel tjeckiska 01-02-2024
Produktens egenskaper Produktens egenskaper tjeckiska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 29-07-2020
Bipacksedel Bipacksedel danska 01-02-2024
Produktens egenskaper Produktens egenskaper danska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 29-07-2020
Bipacksedel Bipacksedel tyska 01-02-2024
Produktens egenskaper Produktens egenskaper tyska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 29-07-2020
Bipacksedel Bipacksedel estniska 01-02-2024
Produktens egenskaper Produktens egenskaper estniska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 29-07-2020
Bipacksedel Bipacksedel grekiska 01-02-2024
Produktens egenskaper Produktens egenskaper grekiska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 29-07-2020
Bipacksedel Bipacksedel franska 01-02-2024
Produktens egenskaper Produktens egenskaper franska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 29-07-2020
Bipacksedel Bipacksedel italienska 01-02-2024
Produktens egenskaper Produktens egenskaper italienska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 29-07-2020
Bipacksedel Bipacksedel lettiska 01-02-2024
Produktens egenskaper Produktens egenskaper lettiska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 29-07-2020
Bipacksedel Bipacksedel litauiska 01-02-2024
Produktens egenskaper Produktens egenskaper litauiska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 29-07-2020
Bipacksedel Bipacksedel ungerska 01-02-2024
Produktens egenskaper Produktens egenskaper ungerska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 29-07-2020
Bipacksedel Bipacksedel maltesiska 01-02-2024
Produktens egenskaper Produktens egenskaper maltesiska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 29-07-2020
Bipacksedel Bipacksedel nederländska 01-02-2024
Produktens egenskaper Produktens egenskaper nederländska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 29-07-2020
Bipacksedel Bipacksedel polska 01-02-2024
Produktens egenskaper Produktens egenskaper polska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 29-07-2020
Bipacksedel Bipacksedel portugisiska 01-02-2024
Produktens egenskaper Produktens egenskaper portugisiska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 29-07-2020
Bipacksedel Bipacksedel rumänska 01-02-2024
Produktens egenskaper Produktens egenskaper rumänska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 29-07-2020
Bipacksedel Bipacksedel slovakiska 01-02-2024
Produktens egenskaper Produktens egenskaper slovakiska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 29-07-2020
Bipacksedel Bipacksedel slovenska 01-02-2024
Produktens egenskaper Produktens egenskaper slovenska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 29-07-2020
Bipacksedel Bipacksedel finska 01-02-2024
Produktens egenskaper Produktens egenskaper finska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 29-07-2020
Bipacksedel Bipacksedel svenska 01-02-2024
Produktens egenskaper Produktens egenskaper svenska 01-02-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 29-07-2020
Bipacksedel Bipacksedel norska 01-02-2024
Produktens egenskaper Produktens egenskaper norska 01-02-2024
Bipacksedel Bipacksedel isländska 01-02-2024
Produktens egenskaper Produktens egenskaper isländska 01-02-2024
Bipacksedel Bipacksedel kroatiska 01-02-2024
Produktens egenskaper Produktens egenskaper kroatiska 01-02-2024

Sök varningar relaterade till denna produkt